- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Hologic completes acquisition of DRC
Bone densitometer firm Hologic has completed its purchase of Direct Radiography Corp. from SDI Holding, the parent company of Agfa subsidiary Sterling Diagnostic Imaging. The deal was valued at around $20 million, consisting of $7 million in cash
Bone densitometer firm Hologic has completed its purchase of Direct Radiography Corp. from SDI Holding, the parent company of Agfa subsidiary Sterling Diagnostic Imaging. The deal was valued at around $20 million, consisting of $7 million in cash and about 1.9 million shares of Hologic common stock. The purchase amount decreased sharply from the initial agreement, which was valued at about $30 million. Hologic was able to get some price concessions in exchange for a speedy closing, said David Ellenbogen, Hologic chairman and CEO.
As a result of the acquisition, Hologic receives about 90 employees, a 168,000-square-foot research, development, manufacturing, and administrative site in Newark, DE, 26 U.S. patents, and a number of foreign patents.
Hologic plans to market DRCs DirectRay digital radiography technology via a number of channels, including OEM opportunities. Discussions with several potential OEM clients are under way, Ellenbogen said.
The company will also participate in the retrofit sector, equipping recently purchased traditional x-ray rooms with DirectRay detectors to pave the way for PACS, he said. In addition to the firms first retrofit site at Brooke Army Medical Center in Fort Sam Houston, TX, DRC has installed a retrofit at an undisclosed location. DRC is taking orders now for retrofits.
Finally, Bedford, MA-based Hologic will continue DRCs direct sales efforts with its traditional iiRAD systems. In future development plans, Hologic expects to bring DirectRay technology suitable for fluoroscopy and mammography applications to market. Commercialization of these products will not occur for at least a year, however, Ellenbogen said.
© 1999 Miller Freeman, Inc.All rights reserved.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
